Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. - Wikidata - awgldk - TriplyDB

Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.

Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.

http://www.wikidata.org/entity/Q34177223

about

Dinosaurs and ancient civilizations: reflections on the treatment of cancer Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review Systemic therapies for pancreatic cancer--the role of pharmacogenetics Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy Equilibrative nucleoside transporters-A review.CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy.Nucleotide metabolism, oncogene-induced senescence and cancer.Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer.Therapeutic options for the management of pancreatic cancer.Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis.MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma Looking to the future: biomarkers in the management of pancreatic adenocarcinoma.Ectopic overexpression of Sonic Hedgehog (Shh) induces stromal expansion and metaplasia in the adult murine pancreas.The interconnectedness of cancer cell signaling.Developments in metastatic pancreatic cancer: is gemcitabine still the standard?Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoi Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model.Development of a metabolites risk score for one-year mortality risk prediction in pancreatic adenocarcinoma patients.A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions.Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer Clinicopathological significance of deoxycytidine kinase expression in esophageal squamous cell carcinoma.Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.Role of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for diagnosis of solid pancreatic masses.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?Molecular endoscopic ultrasound for diagnosis of pancreatic cancer.Role of solute carrier transporters in pancreatic cancer: a review.Current and future biomarkers for pancreatic adenocarcinoma.Equilibrative nucleoside transporter 1 expression in primary human hepatocytes is highly variable and determines uptake of ribavirin.

P2860

Q24628746-1C53A443-3934-4914-8A6A-2875331E2176 Q26767120-EAB01B6B-EAE3-4899-A5BA-027090D3F3DA Q26862139-CE7BEF14-B575-41D1-B656-3FF0D3A7F671 Q27021716-36AA66A1-96FC-4BFA-848A-041BFEFF27AE Q28484288-5E6EF8A8-85B4-4F50-A8DB-0ED06281BD18 Q30244329-B9F018F1-FF3F-4742-9325-7953528CABD1 Q33630872-4C73E08D-96AB-4C60-82A7-D986862D4499 Q33722508-69B347EB-F354-4957-BF91-C9A51BFD14BF Q33969333-606D279F-3DE4-4988-B10E-AC12BF224FEA Q34067856-305F66E6-E640-4AEB-A38D-3CA4CDF328B9 Q34093776-F79E6508-063A-4D7F-BD81-ED06BE1FCAFC Q34205171-A6EA5D02-9641-4270-94DE-AEDD075F367B Q34283650-A61CB4E8-C6CB-4C00-ABF8-71A616ED757B Q34507964-57A25105-45A3-4223-95ED-D475FA50BBA0 Q34957154-9E72DB04-A31F-4447-A6A2-57D93143C45B Q35066350-2EEE6BA1-7E6F-4A97-BBFE-C78901796D5A Q35086475-700C061F-6D1D-46B9-AA3C-94FA9C3A9B4A Q35196518-40981342-B4D9-45DB-A1A3-5C806CDDD63E Q35297202-8C6E6493-615D-4F99-BB0F-406DE60B81B8 Q35444326-1EA17CC2-C540-421E-BD3F-2383E93D8DC2 Q35669733-9559EE12-5A39-4321-92E0-54B2B9A69AF4 Q35776091-BD837563-9932-4161-9264-DBDD0DA78AA6 Q36003248-FDD76FCB-A75B-4946-9167-7A69E70E591B Q36775333-B7B77F3E-95F7-4502-8F4F-E559BB02ECF9 Q36796262-7A1641B2-034B-48FE-8484-CCAEF4DD0421 Q36822149-06F8309F-DDC1-49F9-BFED-BD84B1B1DD6D Q36887757-FDC202B9-07FE-49FE-8D29-D7721E4BE91F Q36962474-6DE074E7-9361-4FF4-BEFD-4B156B2C0E07 Q37268613-EE02632B-CB04-4DF4-AA71-5ED76712042C Q37342736-10BF8AAA-5DD8-4E26-A2C5-663DD047EF19 Q37529964-7D9CAD59-3C44-4D99-B88C-BB1D53B88B1F Q37559699-8EED6741-A6A2-4EFA-9B73-C6419EC030EB Q37569554-792A8FEF-B6C8-4767-A5F4-E6F4E765B083 Q37870995-C75E3698-370B-40B3-BDB1-DA9C66480FAF Q37994505-3BBC4529-58F8-42D5-9DA3-21A8963EE136 Q38125770-578E8620-A75B-46CD-8361-D4F41CE6C93B Q38161338-A32B4E06-7E24-4C99-93EF-DD7B0980E644 Q38236028-C42A4223-4D10-48A8-8D8E-5E83BF8C3727 Q38670577-ED297E6B-F663-4766-80AD-BA8C4FF4653C Q38707179-64E26C04-62F3-4A61-93E5-BCC547750CA8

P2860

Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.

http://www.wikidata.org/entity/Q34177223

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Gene expression levels as pred ...... e-based adjuvant chemotherapy.

@ast

Gene expression levels as pred ...... e-based adjuvant chemotherapy.

@en

Gene expression levels as pred ...... e-based adjuvant chemotherapy.

@nl

type

label

Gene expression levels as pred ...... e-based adjuvant chemotherapy.

@ast

Gene expression levels as pred ...... e-based adjuvant chemotherapy.

@en

Gene expression levels as pred ...... e-based adjuvant chemotherapy.

@nl

prefLabel

Gene expression levels as pred ...... e-based adjuvant chemotherapy.

@ast

Gene expression levels as pred ...... e-based adjuvant chemotherapy.

@en

Gene expression levels as pred ...... e-based adjuvant chemotherapy.

@nl

P1433

Q34177223-8183E32D-E903-4B78-9ACF-A90E5E73D4ED

P1476

Q34177223-DCF2FD71-1925-48B7-8A59-2B519E4BE38B

P2093

Q34177223-0D7BE1FE-3ECA-42FD-A578-4856BD1CD9B2

Q34177223-386C3CD4-586F-4562-9999-806B767A00FA

Q34177223-48258740-805F-4056-BF23-1C3882E0C678

Q34177223-6476C3C2-165C-418A-899F-C01DA00E17D5

Q34177223-6D59E0BB-1333-47A4-81C5-B8032590F8F2

Q34177223-6FD06908-691A-4225-B307-20891DFBD240

Q34177223-86ED2D01-FE23-4A6B-B1BB-ECF24E7FBB43

Q34177223-BBD0CFBD-9174-4074-B0E7-60E44D9E273E

Q34177223-C383A643-AB3F-4C84-A96E-3FA04CB2392E

Q34177223-CFCFBAFA-2ECD-4086-8672-2A2A03A97782

P2860

Q34177223-02CF019B-7CE7-401F-9DBE-7186D48FF507

Q34177223-052D117E-514F-4866-A79B-7B894859A6F5

Q34177223-11D8EC4F-6072-45C5-9665-E04B8927104F

Q34177223-12F726D7-4684-4CDF-AE16-B68F3222A566

Q34177223-17AFA35B-45A1-4490-91D1-305379BFD118

Q34177223-1F115735-DD77-4E65-B7C6-CB6FF5FD7C53

Q34177223-201F68A0-A7EB-42DC-9468-FD1F56DE0B07

Q34177223-2380C776-F823-4F3C-BDED-DC37B35F7776

Q34177223-2E2ED6E3-01D3-429B-8DFF-B6B548AEBAE0

Q34177223-319AA25D-1C59-4A71-9CD6-C7964D84412A

P304

Q34177223-6C2D4374-8401-471F-9A16-E8B424793565

P31

Q34177223-0248D9BA-50B7-4012-9D79-8446BB1246B3

P356

Q34177223-FE7A0827-1B09-4D73-91C8-0A6B6C6364B4

P433

Q34177223-464A1D5D-85C2-4F22-AC8B-0DE71BEFAE62

P478

Q34177223-C793803B-E5E4-42B4-8122-14137011ADEA

P50

Q34177223-2AC9896B-9F1C-4C21-897B-3BC22848617A

Q34177223-B3686F9F-4A8D-49D3-A770-70A14D2E09F6

P577

Q34177223-48A5362B-4873-4D5A-BD3A-EDF3724A1CB8

P5875

Q34177223-0EA14AA8-3669-461C-935A-2BE626A35F70

P698

Q34177223-38E2C0C9-1F57-4BBA-9FBF-7E09FCFDBEF9

P921

Q34177223-53811CC7-9B1D-44A1-8CE6-735ADF11C3D3

P932

Q34177223-F3B8BB3F-2F67-40D3-B7C8-00078F1D7A32

P356

P1433

P1476

Gene expression levels as pred ...... ne-based adjuvant chemotherapy

@en

P2093

Hayato Fujita

http://www.w3.org/2001/XMLSchema#string

Jun Yu

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Mizumoto

http://www.w3.org/2001/XMLSchema#string

Kohei Nakata

http://www.w3.org/2001/XMLSchema#string

Masao Tanaka

http://www.w3.org/2001/XMLSchema#string

Ryota Souzaki

http://www.w3.org/2001/XMLSchema#string

Soichi Itaba

http://www.w3.org/2001/XMLSchema#string

Tadashi Kayashima

http://www.w3.org/2001/XMLSchema#string

Takao Ohtsuka

http://www.w3.org/2001/XMLSchema#string

Tatsuro Tajiri

http://www.w3.org/2001/XMLSchema#string

P2860

Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Cancer statistics, 2009

Quantitative determination of apoptotic death in cultured human pancreatic cancer cells by propidium iodide and digitonin.

Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry

Towards quantitative mRNA analysis in paraffin-embedded tissues using real-time reverse transcriptase-polymerase chain reaction: a methodological study on lymph nodes from melanoma patients.

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.

High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF.

P304

807-817

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.10458

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Kenoki Ohuchida

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47358098

http://www.w3.org/2001/XMLSchema#string

P698

20927319

http://www.w3.org/2001/XMLSchema#string

P921

P932

2950330

http://www.w3.org/2001/XMLSchema#string